($C_3$-$C_6$)cycloalkyl, O($C_3$-$C_6$)cycloalkyl, C=O($C_3$-$C_6$)cycloalkyl, aryl, O-aryl, heteroaryl, or heterocyclyl, wherein said alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted with one or more halogen, ($C_1$-$C_4$)alkyl, ($C_3$-$C_6$)cycloalkyl, $CF_3$, $OCF_3$, $OCH_3$, CN, OH and oxo;

$R^{12}$ is ($C_1$-$C_4$)alkyl, heterocyclyl, cycloalkyl, heteroaryl, aryl, or (C=O)$R^6$, each optionally substituted with one or more substituents independently selected from halogen, ($C_1$-$C_4$)alkyl, and OH; and

$R^{13}$ is ($C_1$-$C_4$)alkyl, heterocyclyl, cycloalkyl, heteroaryl, aryl, or (C=O)$R^6$, each optionally substituted with one or more substituents independently selected from halogen, ($C_1$-$C_4$)alkyl, and OH.

In one aspect, the present disclosure relates to a compound having the formula I:




(I),

or a pharmaceutically acceptable salt thereof, wherein:

n is 0, 1 or 2;

X is $S(O)_2$;

$R^1$ is selected from $NR^aR^b$;

$R^a$ is selected from H;

$R^b$ is H;

A is a 5-membered heteroaryl ring which is substituted with 1 to 3 R groups each independently selected from alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl, wherein said R groups selected from alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl, are optionally substituted with one or more substituents independently selected from $R^{11}$;

$R^2$ is independently halogen, ($C_1$-$C_4$)alkyl, or O($C_1$-$C_4$)alkyl, wherein said alkyl is optionally substituted with one or more halogen;

or, two $R^2$ when both are ($C_1$-$C_4$)alkyl and are attached to the same carbon atom, optionally can come together to form a cyclopropyl, cyclobutyl, or cyclopentyl ring or, two $R^2$ when both are ($C_1$-$C_4$)alkyl and are not attached to the same carbon atom, optionally can come together and form a bridged ring, wherein said cyclopropyl, cyclobutyl, cyclopentyl or bridged

In another aspect, the present disclosure relates to a compound which is




or a pharmaceutically acceptable salt thereof.

The present disclosure also includes pharmaceutical compositions containing a compound of the present disclosure and methods of preparing such pharmaceutical compositions. In another aspect, the present disclosure relates to a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) a compound as defined herein or a pharmaceutically acceptable salt thereof. In another aspect, the present disclosure relates to a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound as defined herein. In another aspect, the present disclosure relates to a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the pharmaceutically acceptable salt as defined herein.

The present disclosure further includes methods of preventing, treating, or ameliorating the cognitive impairments associated with Alzheimer’s disease, Parkinson’s disease, and schizophrenia.

In another aspect, the present disclosure relates to a compound as defined herein, or a pharmaceutically acceptable salt thereof, for use in therapy.

In another aspect, the present disclosure relates to a compound as defined herein, or a pharmaceutically acceptable salt thereof, for use in treating a patient with cognitive impairments associated with Alzheimer’s disease, Parkinson’s disease, and schizophrenia. In another aspect, the present disclosure relates to a compound as defined herein, or a pharmaceutically acceptable salt thereof for use in treating a patient with mild to moderate dementia of the Alzheimer's type.

In another aspect, the present disclosure relates to use of the compound as defined herein, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating cognitive impairments associated with Alzheimer’s disease, Parkinson’s disease, and schizophrenia in a patient in need thereof. In another aspect, the present disclosure relates to use of the compound as defined herein, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of mild to moderate dementia of the Alzheimer's type.

WHAT IS CLAIMED IS:

1. A compound having the formula I:




(I),

or a pharmaceutically acceptable salt thereof, wherein:

n is 0, 1 or 2;

X is $S(O)_2$;

$R^1$ is selected from $NR^aR^b$;

$R^a$ is selected from H;

$R^b$ is H;

A is a 5-membered heteroaryl ring which is substituted with 1 to 3 R groups each independently selected from alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl, wherein said R groups selected from alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl, are optionally substituted with one or more substituents independently selected from $R^{11}$;

$R^2$ is independently halogen, $(C_1\text{-}C_4)$alkyl, or $O(C_1\text{-}C_4)$alkyl, wherein said alkyl is optionally substituted with one or more halogen;

or, two $R^2$ when both are $(C_1\text{-}C_4)$alkyl and are attached to the same carbon atom, optionally can come together to form a cyclopropyl, cyclobutyl, or cyclopentyl ring or, two $R^2$ when both are $(C_1\text{-}C_4)$alkyl and are not attached to the same carbon atom, optionally can come together and form a bridged ring, wherein said cyclopropyl, cyclobutyl, cyclopentyl or bridged ring may be optionally substituted with one or more substituents independently selected from OH, halogen, or $(C_1\text{-}C_4)$alkyl;

$R^3$ is H, halogen or $(C_1\text{-}C_4)$alkyl, wherein said alkyl is optionally substituted with one or more halogen;

$R^4$ is H, halogen or $(C_1\text{-}C_4)$alkyl, wherein said alkyl is optionally substituted with one or more halogen;

or, $R^3$ and $R^4$ optionally can come together to form a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl ring wherein said ring may be optionally substituted with one or more substituents independently selected from OH, halogen, or $(C_1\text{-}C_4)$alkyl;

$R^5$ is H or $(C_1\text{-}C_4)$alkyl;

$R^6$ is H or $(C_1\text{-}C_4)$alkyl;

$R^7$ is H or $(C_1\text{-}C_4)$alkyl;

$R^8$ is OH, $(C_1\text{-}C_4)$alkyl, aryl, heteroaryl, or heterocyclyl;

$R^9$ is aryl, heteroaryl, or heterocyclyl;

$R^{10}$ is methyl or hydroxyl;

$R^{11}$ is halogen, OH, oxo, $CF_3$, $OCF_3$, CN, $(C_1\text{-}C_6)$alkyl, $O(C_1\text{-}C_6)$alkyl, $S(C_1\text{-}C_4)$alkyl, $C{=}O(C_1\text{-}C_4)$alkyl, $NR^{12}R^{13}$, $(C{=}O)NR^6R^7$, $(C{=}O)OR^6$, $(C_2\text{-}C_4)$alkenyl, $(C_2\text{-}C_4)$alkynyl, $(C_3\text{-}C_6)$cycloalkyl, $O(C_3\text{-}C_6)$cycloalkyl, $C{=}O(C_3\text{-}C_6)$cycloalkyl, aryl, O-aryl, heteroaryl, or heterocyclyl, wherein said alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted with one or more halogen, $(C_1\text{-}C_4)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $CF_3$, $OCF_3$, $OCH_3$, CN, OH and oxo;

$R^{12}$ is $(C_1\text{-}C_4)$alkyl, heterocyclyl, cycloalkyl, heteroaryl, aryl, or $(C{=}O)R^6$, each optionally substituted with one or more substituents independently selected from halogen, $(C_1\text{-}C_4)$alkyl, and OH; and

$R^{13}$ is $(C_1\text{-}C_4)$alkyl, heterocyclyl, cycloalkyl, heteroaryl, aryl, or $(C{=}O)R^6$, each optionally substituted with one or more substituents independently selected from halogen, $(C_1\text{-}C_4)$alkyl, and OH.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^2$ is independently methyl, ethyl or F.

3. The compound of any one of claims 1 to 2, or a pharmaceutically acceptable salt thereof, wherein A is a 5-membered heteroaryl ring which is substituted with 1 R group independently selected from OH, oxo, $NR^6R^7$, CN, alkoxy, halogen, aminoalkyl, hydroxyalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl, wherein said R group selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl, are further optionally substituted with one or more substituents independently selected from $R^{11}$.

4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R is alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted with one or more substituents independently selected from $R^{11}$.

5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R is cyclohexyl, phenyl, pyrazolyl, pyridinyl or isoxazolyl, each optionally substituted with one or more substituents independently selected from $R^{11}$.

6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein $R^3$ and $R^4$ are independently selected from H, F, and methyl.

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having the formula (II):




(II),

or a pharmaceutically acceptable salt thereof, wherein;

m is 0, 1, 2 or 3;

Z is independently selected from F, Cl, Br, methyl, methoxy, ethyl, ethoxy, propyl, $-CH_2OH$, $-CH_2CH_2OH$, $-CF_3$, $-CH_2CF_3$, $-OCF_3$, $-OCHF_2$, $-OCH_2CF_3$, and cyclopropyl;

Ring A is oxadiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, isothiazolyl, thiazolyl, pyrazolyl or imidazolyl;

Ring B is cyclohexyl, phenyl, pyrazolyl, pyridinyl or isoxazolyl;

$R^3$ is H, F or $(C_1\text{-}C_4)$alkyl, wherein said alkyl is optionally substituted with one or more halogen; and

$R^4$ is H, F or $(C_1\text{-}C_4)$alkyl, wherein said alkyl is optionally substituted with one or more halogen.

8. The compound of claim 7, or a pharmaceutically acceptable salt thereof, having the formula (II) or a pharmaceutically acceptable salt thereof, wherein;

m is 0, 1 or 2;

Z is independently selected from F, Cl, Br, methyl, methoxy, ethyl, ethoxy, propyl, $-CH_2OH$, $-CH_2CH_2OH$, $-CF_3$, $-CH_2CF_3$, $-OCF_3$, $-OCHF_2$, $-OCH_2CF_3$, and cyclopropyl;

Ring A is oxadiazolyl, oxazolyl, isoxazolyl, or thiazolyl;

Ring B is phenyl, pyrazolyl, pyridinyl or isoxazolyl; and

$R^3$ and $R^4$ are both H, or $R^3$ and $R^4$ are both F.

9. The compound of claim 1 which is selected from the group consisting of (1*R*)-1-{5-[2-Methyl-5-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-[5-(2,5-Dimethylphenyl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
4,4-Difluoro-1-{3-[3-(2,2,2-trifluoroethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide, diastereomer C;
1-{3-[3-(Difluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-4-fluoro-6-azaspiro[2.5]octane-6-sulfonamide, diastereomer E;
(1*R*)-1-{3-[4-Fluoro-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
1-{3-[4-Fluoro-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-4-methyl-6-azaspiro[2.5]octane-6-sulfonamide, diastereomer D;
(1*R*)-1-{2-[3-(Trifluoromethoxy)phenyl]-1,3-thiazol-4-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-{5-[4-Methyl-1-(2,2,2-trifluoroethyl)-1*H*-pyrazol-5-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-2-[5-(1,4-Dimethyl-1*H*-pyrazol-5-yl)-1,2,4-oxadiazol-3-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-2-{5-[2-(Difluoromethoxy)pyridin-4-yl]-1,2,4-oxadiazol-3-yl}-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-2-[3-(3-Cyclopropylisoxazol-4-yl)-1,2,4-oxadiazol-5-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-1,1-Difluoro-2-{3-[1-(2,2,2-trifluoroethyl)-1*H*-pyrazol-5-yl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-2-{5-[2-(Difluoromethoxy)-5-methylpyridin-4-yl]-1,2,4-oxadiazol-3-yl}-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-1,1-Difluoro-2-{5-[1-methyl-4-(trifluoromethyl)-1*H*-pyrazol-5-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-{1-[3-(Trifluoromethoxy)phenyl]-1*H*-pyrazol-4-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-2-[5-(1-Cyclopropyl-1*H*-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*S*)-2-[5-(1-Cyclopropyl-1*H*-pyrazol-5-yl)-1,3,4-thiadiazol-2-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-[5-(6,7-Dihydro-4*H*-pyrazolo[5,1-c][1,4]thiazin-3-yl)-1,2,4-oxadiazol-3-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-{5-[1-methyl-3-(trifluoromethyl)-1*H*-pyrazol-4-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-[5-(2-methyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-[5-(1,3,4-trimethyl-1*H*-pyrazol-5-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[4-(3-Cyclopropylisoxazol-4-yl)-1,3-oxazol-2-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-{2-[4-fluoro-2-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-[5-(1-Cyclopropyl-4-methyl-1*H*-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(1-Ethyl-5-methyl-1*H*-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(3-Cyclopropyl-5-methylisoxazol-4-yl)-1,3-oxazol-2-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-{5-[1-Cyclopropyl-3-(trifluoromethyl)-1*H*-pyrazol-5-yl]-1,2,4-oxadiazol-3-yl}-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-[5-(2-Cyclopropyl-5-methylphenyl)-1,2,4-oxadiazol-3-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-[2-(3-Cyclopropylisoxazol-4-yl)-1,3-oxazol-4-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(2-Methylphenyl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-[5-(2,5-Dimethylphenyl)-1,2,4-oxadiazol-3-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-{2-[2-(Difluoromethoxy)pyridin-4-yl]-1,3-oxazol-4-yl}-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

1,1-Difluoro-2-{1-[4-fluoro-2-(trifluoromethyl)phenyl]-1*H*-pyrazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

1,1-Difluoro-2-{5-[4-fluoro-2-(trifluoromethyl)phenyl]-1,2,4-thiadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[3-(5-Chloro-2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-1,1-Difluoro-2-(3-phenyl-1,2,4-oxadiazol-5-yl)-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-1,1-Difluoro-2-{3-[4-fluoro-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-{3-[5-Fluoro-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-{3-[3-(Difluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-1,1-Difluoro-2-[3-(3-fluorophenyl)-1,2,4-oxadiazol-5-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-2-[3-(2,4-Difluorophenyl)-1,2,4-oxadiazol-5-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-1,1-Difluoro-2-{3-[4-(2-hydroxypropan-2-yl)phenyl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
1-{3-[2-(Methylamino)pyridin-3-yl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
1-{3-[2-(Pyrrolidin-1-yl)pyridin-4-yl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
2-[3-(3,5-Dimethylisoxazol-4-yl)-1,2,4-oxadiazol-5-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-[3-(3-Cyclopropylisoxazol-4-yl)-1,2,4-oxadiazol-5-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-2-[3-(3-Cyclopropyl-5-methylisoxazol-4-yl)-1,2,4-oxadiazol-5-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-2-(3-Cyclohexyl-1,2,4-oxadiazol-5-yl)-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-1,1-Difluoro-2-[3-(2-methylpyridin-3-yl)-1,2,4-oxadiazol-5-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-1,1-Difluoro-2-{3-[2-(trifluoromethyl)pyridin-4-yl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-2-{3-[2-(Difluoromethoxy)pyridin-4-yl]-1,2,4-oxadiazol-5-yl}-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-2-[3-(1-Cyclopropyl-4-methyl-1*H*-pyrazol-5-yl)-1,2,4-oxadiazol-5-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-[3-(imidazo[1,2-a]pyridin-7-yl)-1,2,4-oxadiazol-5-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{3-[5-Cyclopropyl-3-(trifluoromethyl)isoxazol-4-yl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

1-[3-(5-Chloro-2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-[3-(1-Cyclopropyl-1*H*-pyrazol-5-yl)-1,2,4-oxadiazol-5-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-{3-[3-Cyclopropyl-5-(trifluoromethyl)isoxazol-4-yl]-1,2,4-oxadiazol-5-yl}-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-{3-[5-Cyclopropyl-3-(trifluoromethyl)isoxazol-4-yl]-1,2,4-oxadiazol-5-yl}-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

1,1-Dichloro-2-{3-[4-fluoro-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[3-(Trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(5-Chloro-2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(2-Cyanophenyl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[2-(Difluoromethoxy)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[4-(Trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[5-Bromo-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[4-Chloro-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-(5-Phenyl-1,2,4-oxadiazol-3-yl)-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[2-(Difluoromethoxy)-4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[4-Chloro-2-(difluoromethoxy)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[3-(Difluoromethoxy)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[2-Fluoro-6-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-[5-(4-Methoxyphenyl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-{5-[4-(Difluoromethoxy)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-[5-(2,4-Difluorophenyl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-{5-[4-Fluoro-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-{5-[2-(Trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-{5-[2-(2,2,2-Trifluoroethoxy)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-[5-(2,4-Dimethylphenyl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-{5-[2-(Trifluoromethoxy)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-{5-[5-Fluoro-2-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-{5-[5-Chloro-2-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-{5-[4-(2-Hydroxypropan-2-yl)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-{5-[2-(Difluoromethoxy)-4-fluorophenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-[5-(2,4,5-Trimethylphenyl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-2-[5-(2-Cyclopropylphenyl)-1,2,4-oxadiazol-3-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-[5-(5-Fluoro-2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-[5-(1-Cyclopropyl-3-methyl-1*H*-indol-5-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-[5-(2-Methylpyridin-3-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-{5-[3-(Propan-2-yl)cyclobutyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[2-Fluoro-6-(trifluoromethyl)benzyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[2-Fluoro-5-(trifluoromethyl)benzyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(2,6-Dimethylbenzyl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(3-Methylcyclohexyl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[1-(2-Chlorophenyl)ethyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[5-Fluoro-2-(trifluoromethyl)benzyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[1-(2,5-Difluorophenyl)cyclobutyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(Spiro[2.5]oct-4-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[4-Fluoro-2-(trifluoromethyl)benzyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(4-Fluoro-2,3-dihydro-1*H*-inden-1-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-(5-{1-[3-(Trifluoromethyl)phenyl]cyclopropyl}-1,2,4-oxadiazol-3-yl)-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(3-Phenylcyclobutyl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(3,6-Dimethylpyridin-2-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[6-(Trifluoromethyl)pyridin-2-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[2-(2,2,2-Trifluoroethoxy)pyridin-4-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[3-Methyl-6-(trifluoromethyl)pyridin-2-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(Spiro[3.3]hept-2-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(1-Ethyl-3-methyl-1*H*-pyrazol-5-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[1-(2,2,2-Trifluoroethyl)-1*H*-pyrazol-4-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[4-(Trifluoromethyl)-1,3-oxazol-5-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(4-Ethyl-1,3-oxazol-5-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[1-(2,2,2-Trifluoroethyl)-1*H*-pyrazol-3-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(3-Cyclopropylisoxazol-4-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(4,5-Dimethylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[(3,5-Dimethylisoxazol-4-yl)methyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[3-(Trifluoromethyl)isoxazol-4-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(1-Cyclopropyl-1*H*-pyrazol-5-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[2-(1*H*-Imidazol-1-yl)-5-(trifluoromethyl)pyridin-4-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[1-Methyl-4-(trifluoromethyl)-1*H*-pyrazol-5-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-{5-[2-(Cyclopropyloxy)pyridin-4-yl]-1,2,4-oxadiazol-3-yl}-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-[5-(1-Cyclopropyl-1*H*-pyrazol-5-yl)-1,2,4-oxadiazol-3-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-[5-(1-*tert*-Butyl-1*H*-pyrazol-5-yl)-1,2,4-oxadiazol-3-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-[5-(3-methylimidazo[1,2-a]pyridin-7-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-[5-(3-Cyclopropyl-1-ethyl-1*H*-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-{5-[1-methyl-5-(trifluoromethyl)-1*H*-pyrazol-4-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-{5-[1-*tert*-Butyl-5-(trifluoromethyl)-1*H*-pyrazol-4-yl]-1,2,4-oxadiazol-3-yl}-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-[5-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-[5-(1-Cyclopropyl-4-methyl-1*H*-pyrazol-5-yl)-1,2,4-oxadiazol-3-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-[5-(5,6-Dihydro-4*H*-pyrrolo[1,2-b]pyrazol-3-yl)-1,2,4-oxadiazol-3-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-[5-(1-methyl-1*H*-pyrazol-5-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-[5-(1-methyl-1,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-{5-[1-methyl-3-(trifluoromethyl)-1*H*-pyrazol-5-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-{5-[1-Cyclopropyl-5-(trifluoromethyl)-1*H*-pyrazol-3-yl]-1,2,4-oxadiazol-3-yl}-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-[5-(2-Cyclopropyl-4,5,6,7-tetrahydro-2*H*-indazol-3-yl)-1,2,4-oxadiazol-3-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-{5-[1-Cyclopropyl-4-(trifluoromethyl)-1*H*-pyrazol-5-yl]-1,2,4-oxadiazol-3-yl}-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-[5-(3-Cyclopropylpyridazin-4-yl)-1,2,4-oxadiazol-3-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(3-Cyclopropylpyridazin-4-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-{5-[2-(propan-2-yloxy)pyridin-4-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(1,4-Dimethyl-1*H*-pyrazol-5-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-[5-(4*H*-pyrazolo[1,5-c][1,3]thiazol-3-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-{5-[1-Cyclopropyl-5-methyl-3-(trifluoromethyl)-1*H*-pyrazol-4-yl]-1,2,4-oxadiazol-3-yl}-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-2-{5-[3-Cyclopropyl-5-(trifluoromethyl)isoxazol-4-yl]-1,2,4-oxadiazol-3-yl}-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-[5-(pyridin-3-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[4-(Trifluoromethyl)pyridin-3-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[2-(Trifluoromethyl)pyridin-3-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[2-(2,2,2-Trifluoroethoxy)pyridin-3-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[5-(2,2,2-Trifluoroethoxy)pyridin-3-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[2-Methyl-5-(trifluoromethyl)pyridin-3-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[1-(Propan-2-yl)-1*H*-pyrazol-5-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[6-(2,2,2-Trifluoroethoxy)pyridin-3-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(1-Cyclopropyl-4-methyl-1*H*-pyrazol-5-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(2-Methyl-4,5,6,7-tetrahydro-2*H*-indazol-3-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-[5-(2-methyl-4,5,6,7-tetrahydro-2*H*-indazol-3-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-[5-(pyridin-2-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-{5-[3-(trifluoromethyl)isoxazol-4-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(2,3-Dihydro-1*H*-inden-4-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-(5-{3-[5-(Trifluoromethyl)-1*H*-pyrazol-1-yl]phenyl}-1,2,4-oxadiazol-3-yl)-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(2-Phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(5,6,7,8-Tetrahydronaphthalen-2-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[2-(1*H*-Pyrrol-1-yl)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(4'-Fluorobiphenyl-3-yl)-1,2,4-oxadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[2-(1-Cyanocyclopropyl)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[2-(Pyrimidin-2-yl)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[2-(1*H*-Pyrazol-1-yl)phenyl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[3-(2,2,2-Trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[4-Fluoro-2-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[3-(Trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[3-(Trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(2,5-Difluorophenyl)-1,3,4-thiadiazol-2-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(5-Fluoro-2-methylphenyl)-1,3,4-oxadiazol-2-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[2-(2,2,2-Trifluoroethoxy)phenyl]-1,3,4-oxadiazol-2-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[2-(2,2,2-Trifluoroethoxy)phenyl]-1,3,4-thiadiazol-2-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(2-Methylphenyl)-1,3,4-thiadiazol-2-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[4-Fluoro-2-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-{5-[3-(Difluoromethoxy)phenyl]-1,3,4-thiadiazol-2-yl}-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(3-Cyclopropyl-5-methylisoxazol-4-yl)-1,3,4-oxadiazol-2-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-[5-(3-Cyclopropyl-5-methylisoxazol-4-yl)-1,3,4-thiadiazol-2-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(2*R*)-1,1-Difluoro-2-[5-(2-methylphenyl)-1,3,4-thiadiazol-2-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

(1*R*)-1-(4-Phenyl-1,3-oxazol-2-yl)-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-[2-(3-Cyclopropylisoxazol-4-yl)-1,3-thiazol-4-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
(1*R*)-1-[1-(3,5-Dimethylisoxazol-4-yl)-1*H*-pyrazol-4-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-2-[2-(3-Cyclopropylisoxazol-4-yl)-1,3-thiazol-4-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-2-{3-[2-(Difluoromethoxy)pyridin-4-yl]isoxazol-5-yl}-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-2-[4-(3-Cyclopropylisoxazol-4-yl)-1-methyl-1*H*-imidazol-2-yl]-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-2-(3'-Cyclopropyl-3,4'-biisoxazol-5-yl)-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-1,1-Difluoro-2-{4-[4-fluoro-2-(trifluoromethyl)phenyl]-1,3-oxazol-2-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(1*S*)-1-[3-(5-Chloro-2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
(2*S*)-1,1-Difluoro-2-{3-[4-fluoro-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
(2*S*)-2-(3-Cyclohexyl-1,2,4-oxadiazol-5-yl)-1,1-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;
(2*S*)-1,1-Difluoro-2-[3-(3-fluorophenyl)-1,2,4-oxadiazol-5-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
(2*S*)-1,1-Difluoro-2-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
(2*R*)-1,1-Difluoro-2-[5-(2-methylphenyl)-1,3,4-thiadiazol-2-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
1-{3-[3-(Difluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-4-fluoro-6-azaspiro[2.5]octane-6-sulfonamide;
1-{3-[3-(Difluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-4-fluoro-6-azaspiro[2.5]octane-6-sulfonamide;
4,4-Difluoro-1-(3-phenyl-1,2,4-oxadiazol-5-yl)-6-azaspiro[2.5]octane-6-sulfonamide;
1-[3-(2,5-Dimethylphenyl)-1,2,4-oxadiazol-5-yl]-4,4-difluoro-6-azaspiro[2.5]octane-6-sulfonamide;
4-Methyl-1-{3-[2-(2,2,2-trifluoroethoxy)pyridin-4-yl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
1-[3-(3-Cyclopropylisoxazol-4-yl)-1,2,4-oxadiazol-5-yl]-4-fluoro-6-azaspiro[2.5]octane-6-sulfonamide;

1-[3-(3-Cyclopropylisoxazol-4-yl)-1,2,4-oxadiazol-5-yl]-4-fluoro-6-azaspiro[2.5]octane-6-sulfonamide;
1-[3-(3-Cyclopropylisoxazol-4-yl)-1,2,4-oxadiazol-5-yl]-4-fluoro-6-azaspiro[2.5]octane-6-sulfonamide;
1-[3-(3-Cyclopropylisoxazol-4-yl)-1,2,4-oxadiazol-5-yl]-4-fluoro-6-azaspiro[2.5]octane-6-sulfonamide;
1-[3-(3-Cyclopropylisoxazol-4-yl)-1,2,4-oxadiazol-5-yl]-4-fluoro-6-azaspiro[2.5]octane-6-sulfonamide;
2-[3-(3-Cyclopropylisoxazol-4-yl)-1,2,4-oxadiazol-5-yl]-1,1,4-trifluoro-6-azaspiro[2.5]octane-6-sulfonamide;
2-[3-(3-Cyclopropylisoxazol-4-yl)-1,2,4-oxadiazol-5-yl]-1,1,4-trifluoro-6-azaspiro[2.5]octane-6-sulfonamide;
2-[3-(3-Cyclopropylisoxazol-4-yl)-1,2,4-oxadiazol-5-yl]-1,1,4-trifluoro-6-azaspiro[2.5]octane-6-sulfonamide;
2-[3-(3-Cyclopropylisoxazol-4-yl)-1,2,4-oxadiazol-5-yl]-1,1,4-trifluoro-6-azaspiro[2.5]octane-6-sulfonamide;
1,1,4-Trifluoro-2-{3-[4-fluoro-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
1,1,4-Trifluoro-2-{3-[4-fluoro-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
1,1,4-Trifluoro-2-{3-[4-fluoro-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
1,1-Difluoro-2-{3-[4-fluoro-2-(trifluoromethyl)phenyl]-1,2,4-thiadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
1-Fluoro-2-{3-[4-fluoro-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
1-{3-[4-Fluoro-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-2-methyl-6-azaspiro[2.5]octane-6-sulfonamide;
2-{3-[4-Fluoro-2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1,1-dimethyl-6-azaspiro[2.5]octane-6-sulfonamide;
1,1-Difluoro-2-{5-[4-fluoro-2-(trifluoromethyl)phenyl]isothiazol-3-yl}-6-azaspiro[2.5]octane-6-sulfonamide;
1,1-Difluoro-2-[5-(piperidin-1-yl)-1,2,4-thiadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;
1,1-Difluoro-2-[5-(piperidin-1-yl)-1,2,4-thiadiazol-3-yl]-6-azaspiro[2.5]octane-6-sulfonamide;

3'-[5-(2,5-Dimethylphenyl)-1,2,4-oxadiazol-3-yl]-2',2'-difluoro-3-azaspiro[bicyclo[3.2.1]octane-8,1'-cyclopropane]-3-sulfonamide; and
2-[5-(2,5-Dimethylphenyl)-1,2,4-oxadiazol-3-yl]-1,1-difluoro-5-methyl-6-azaspiro[2.5]octane-6-sulfonamide;
or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) a compound of any one of claims 1-9 or a pharmaceutically acceptable salt thereof.

11. The pharmaceutical composition of claim 10, further comprising a second therapeutic agent selected from the group consisting of acetylcholinesterase inhibitors; NMDA receptor antagonists; antipsychotics; MAO-B inhibitors; and levodopa.

12. A compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, for use in therapy.

13. A use of the compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating cognitive impairments associated with Alzheimer's disease, Parkinson's disease, and schizophrenia in a patient in need thereof.

14. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, for use in treating a patient with cognitive impairments associated with Alzheimer's disease, Parkinson's disease, and schizophrenia.

15. A compound which is



,

or a pharmaceutically acceptable salt thereof.

16. A compound according to claim 15 which is



.

17. A compound according to claim 15 which is a pharmaceutically acceptable salt of



.

18. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 16.

19. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the pharmaceutically acceptable salt of claim 17.

20. The compound of any one of claims 15 to 17, or a pharmaceutically acceptable salt thereof for use in treating a patient with mild to moderate dementia of the Alzheimer's type.

21. Use of the compound of any one of claims 15 to 17, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of mild to moderate dementia of the Alzheimer's type.

22. A compound which is



,

or a pharmaceutically acceptable salt thereof.

23. A compound according to claim 22 which is



.

24. A compound according to claim 22 which is a pharmaceutically acceptable salt of  .

25. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 23.

26. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 24.

27. The compound of any one of claims 22 to 24, or a pharmaceutically acceptable salt thereof for use in treating a patient with mild to moderate dementia of the Alzheimer's type.

28. Use of the compound of any one of claims 22 to 24, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of mild to moderate dementia of the Alzheimer's type.

29. A compound which is



,

or a pharmaceutically acceptable salt thereof.

30. A compound according to claim 29 which is



.

31. A compound according to claim 29 which is a pharmaceutically acceptable salt of



.

32. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 30.

33. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 31.

34. The compound of any one of claims 29 to 31, or a pharmaceutically acceptable salt thereof for use in treating a patient with mild to moderate dementia of the Alzheimer's type.

35. Use of the compound of any one of claims 29 to 31, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of mild to moderate dementia of the Alzheimer's type.

36. A compound which is



,

or a pharmaceutically acceptable salt thereof.

37. A compound according to claim 36 which is



.

38. A compound according to claim 36 which is a pharmaceutically acceptable salt of



.

39. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 37.

40. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 38.

41. The compound of any one of claims 36 to 38, or a pharmaceutically acceptable salt thereof for use in treating a patient with mild to moderate dementia of the Alzheimer's type.

42. Use of the compound of any one of claims 36 to 38, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of mild to moderate dementia of the Alzheimer's type.

43. A compound which is



,

or a pharmaceutically acceptable salt thereof.

44. A compound according to claim 43 which is



.

45. A compound according to claim 43 which is a pharmaceutically acceptable salt of



.

46. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 44.

47. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 45.

48. The compound of any one of claims 43 to 45, or a pharmaceutically acceptable salt thereof for use in treating a patient with mild to moderate dementia of the Alzheimer's type.

49. Use of the compound of any one of claims 43 to 45, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of mild to moderate dementia of the Alzheimer's type.

50. A compound which is



,

or a pharmaceutically acceptable salt thereof.

51. A compound according to claim 50 which is



.

52. A compound according to claim 50 which is a pharmaceutically acceptable salt of



.

53. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 51.

54. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 52.

55. The compound of any one of claims 50 to 52, or a pharmaceutically acceptable salt thereof for use in treating a patient with mild to moderate dementia of the Alzheimer's type.

56. Use of the compound of any one of claims 50 to 52, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of mild to moderate dementia of the Alzheimer's type.

57. A compound which is



,

or a pharmaceutically acceptable salt thereof.

58. A compound according to claim 57 which is



.

59. A compound according to claim 57 which is a pharmaceutically acceptable salt of



.

60. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 58.

61. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 59.

62. The compound of any one of claims 57 to 59, or a pharmaceutically acceptable salt thereof for use in treating a patient with mild to moderate dementia of the Alzheimer's type.

63. Use of the compound of any one of claims 57 to 59, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of mild to moderate dementia of the Alzheimer's type.